|
Response
|
SVR12 (N = 1358)
|
Heterogeneity
|
Pb-value
|
Studies
|
|---|
| |
Total, n/N
|
Rate (95%CI)
|
I2(%)
|
P
a
| | |
|---|
|
Overall
|
1296/1358
|
96.3 (95.1–97.4)
|
42
|
0.08
| |
10
|
|
By the different duration of treatment
|
0.9237
| |
|
12 weeks
|
394/415
|
96.2 (92.6–98.8)
|
41
|
0.13
| |
6
|
|
24 weeks
|
52/55
|
96.6 (82.5–100.0)
|
65
|
0.09
| |
2
|
|
By regimens
|
0.8563
| |
|
OBV/PTV/r ± DSV ± RBV
|
811/850
|
96.4 (94.8–97.7)
|
25
|
0.21
| |
10
|
|
OBV/PTV/r ± RBV
|
152/159
|
98.9 (95.3–100.0)
|
0.0
|
0.99
| |
3
|
|
By genotypes
|
0.8424
| |
|
1
|
1025/1076
|
96.2 (94.8–97.4)
|
38
|
0.13
| |
8
|
|
4
|
149/156
|
98.8 (95.1–100.0)
|
0
|
0.99
| |
3
|
|
By treatment history
|
0.8281
| |
|
TN patients
|
423/440
|
96.8 (94.8–98.5)
|
41
|
0.15
| |
5
|
|
TE patients
|
273/285
|
98.9 (96.4–100.0)
|
50
|
0.09
| |
5
|
|
By the presence or absence of cirrhosis
|
0.3887
| |
|
Cirrhosis
|
218/230
|
97.8 (94.6–99.8)
|
43
|
0.12
| |
6
|
|
Non-cirrhosis
|
899/935
|
96.7 (95.3–97.8)
|
20
|
0.28
| |
6
|
- *OBV ombitasvir; PTV paritaprevir, r ritonavir, DSV dasabuvir; RBV ribavirin, TN treatment-naive, TE treatment-experienced, CI confidence interval
- aTest of heterogeneity
- bTest for subgroup differences
